Elutia Announces New Peer Reviewed Publication Highlighting The Robustness Of EluPro, Company's Antibiotic-Eluting BioEnvelope For Implantable Devices
Portfolio Pulse from Benzinga Newsdesk
Elutia Inc. has published preclinical data showing that its product, EluPro, effectively eradicates bacteria associated with cardiac implant infections. This antibiotic-eluting bio-envelope, cleared by the FDA, reduces bacterial colonization with minimal systemic antibiotic exposure.
September 18, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elutia Inc. has released promising preclinical data for EluPro, an FDA-cleared antibiotic-eluting bio-envelope, showing its effectiveness in reducing bacterial colonization in cardiac implants.
The publication of positive preclinical data for EluPro, an FDA-cleared product, is likely to boost investor confidence in Elutia's innovative solutions, potentially leading to a positive short-term impact on ELUT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100